Determination of Genotoxic alkyl p-toluene Sulfonates in Cabazitaxel using LC-MS Method

Bavireddi       Mohan; Ramayanam    Siva Kameswara   Sharma; Devarakonda   Ravi    Kumar; Seshagiri    Vijaya    Murali Mohan Rao; Nutulapati    Venkata    Satya Venugopal

doi:10.2174/1573412915666190522085818

Abstract

Introduction: A suitable LC-MS method for the quantitative determination of genotoxic impurities such as alkyl p-toluene sulfonates in Cabazitaxel was developed. Alkyl p-toluene sulfonates were estimated by LC-MS method using Waters Symmetry C18 (75×4.6 mm), 3.5 µ column.

Materials and Methods: Column temperature was maintained 40 °C. Injection volume was 10 µL and flow rate was set as 0.8 mL/min. Sampler temperature was maintained to 25 °C and run time was set as 25 minutes. The mobile phase was a mixture of ammonium acetate buffer and acetonitrile in 70:30(v/v) was used.

Results: The method validation has been carried as per ICH guidelines. LOQ was found to be 2.66 µg/mL, 2.75 µg/mL and 2.55 µg/mL for MPTS, EPTS and IPPTS Alkyl p-Toluene Sulfonates (APTS) respectively.

Conclusion: The proposed Liquid chromatography-Mass spectroscopy method that can quantify genotoxic APTS in Cabazitaxel at low-level concentration has been developed and validated as per ICH guidelines. Hence, the proposed method was recommended for the assay of genotoxic impurities of cabazitaxel in dosage forms in busy pharmaceutical laboratories.

Keywords: Genotoxic impurities, cabazitaxel, Liquid Chromatography-Mass Spectrometry (LC-MS) validation, limit of quantitation, alkyl p-toluene, cancer.

« Previous Next »

Graphical Abstract

[1] 
Cheetham, P.; Petrylak, D.P. Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J.,  2013, 19(1), 59-65.
[http://dx.doi.org/10.1097/PPO.0b013e3182828d38] [PMID:  23337758] 
[2] 

Assessment report for Jevtana (Cabazitaxel), Procedure no.: EMEA/H/C/002018. In:  ; European Medicines Agency: London, 2011. 
[3] 
Jevtana (Cabazitaxel) injection approved by U.S. FDA after priority review” (Press release). Sanofi-Aventis., 2010.
[4] 
Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer,  2004, 4(4), 253-265.
[http://dx.doi.org/10.1038/nrc1317] [PMID:  15057285] 
[5] 
Oudard, S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol.,  2011, 7(4), 497-506.
[http://dx.doi.org/10.2217/fon.11.23] [PMID:  21463139] 
[6] 
Pivot, X.; Koralewski, P.; Hidalgo, J.L.; Chan, A.; Gonçalves, A.; Schwartsmann, G.; Assadourian, S.; Lotz, J.P. A multicenter phase II study of XRP6258 administered as a 1-H I.V. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol.,  2008, 19(9), 1547-1552.
[http://dx.doi.org/10.1093/annonc/mdn171] [PMID:  18436520] 
[7] 
Kishore, G. New spectrophotometric methods for the quantitative estimation of Cabazitaxel in formulations. Int. J. Res. Rev. Pharm. Applied Sci.,  2012, 2(5), 950-958.
[8] 
Li, C.; Lan, G.; Jiang, J.; Sun, M.; Hang, T. Development and validation of a stability indicating HPLC method for the determination of the impurities in Cabazitaxel. Chromatographia,  2015, 78, 825-831.
[http://dx.doi.org/10.1007/s10337-015-2900-4] 
[9] 
Annapurna, M.M.; Pramadvara, K.; Venkatesh, B.; Sowjanya, G. Stability indicating RP-HPLC method for the determination of Cabazitaxel, Indo American. J. Pharm. Res.,  2013, 3(11), 9262-9269.
[10] 
Annapurna, M.M.; Venkatesh, B.; Naga Supriya, G. A validated stability-indicating liquid chromatographic method for determination of Cabazitaxel-A novel microtubule inhibitor. J. Bioequivalence Bioavailab.,  2014, 6(4), 134-138.
[11] 
Annapurna, M.M.; Venkatesh, B.; Pramadvara, K.; Hemchand, S. Development and validation of a stability indicating liquid chromatographic method for the assay of Cabazitaxel. Chem. Sci. Trans.,  2014, 3(2), 854-860.
[12] 
Patrol, J.V.; Rao, N.R.; Tripathy, N.K. LC-MS/MS determination of Cabazitaxel in rat whole blood on dry blood Spots. Open Access. Sci. Rep.,  2012, 1(6), 1-4.
[13] 
Kort, A.; Hillebrand, M.J.X.; Cirkel, G.A.; Voest, E.E.; Schinkel, A.H.; Rosing, H.; Schellens, J.H.; Beijnen, J.H. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2013, 925, 117-123.
[http://dx.doi.org/10.1016/j.jchromb.2013.02.034] [PMID:  23542607] 
[14] 
De Brujin, P.; de Graan, A-J.M.; Nieuweboer, A.; Ron, H.J.M.; Lam, M-H.; de Wit, R.; Wiemer, E.A.C.; Loos, W.J. Quantification of Cabazitaxel in human plasma by liquid chromatography/triple quadrupole mass spectrometry: A practical solution for non-specific binding. J. Pharm. Biomed. Anal.,  2012, 59, 117-122.
[http://dx.doi.org/10.1016/j.jpba.2011.10.010] 

Rights & Permissions Print Cite

Article Metrics

30

2

1

Explore Articles

Open Access

Open Access Articles

DOI https://dx.doi.org/10.2174/1573412915666190522085818	Print ISSN 1573-4129
Publisher Name Bentham Science Publisher	Online ISSN 1875-676X

Current Pharmaceutical Analysis

Determination of Genotoxic alkyl p-toluene Sulfonates in Cabazitaxel using LC-MS Method

Abstract Play Pause

Graphical Abstract

Abstract